EUVIMEDEUVIMED entdecken
Vergleichsstudie

Procalcitonin as a Tumour Marker in Medullary Thyroid Carcinoma: A Comparative Study with Calcitonin and Carcinoembryonic Antigen

Stylianos Kopanos, Ahmed Hossam Khalil, Sandra Nicole Scheel, Michael Wehmeier, Joachim Feldkamp

Hormone and Metabolic Research · 01.02.2026 · 58 (02) · 63-69

DOI: 10.1055/a-2794-3447 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.02.2026. Verfasst von Stylianos Kopanos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Academic Department of Endocrinology, Diabetes and Infectiology, Klinikum Bielefeld, Klinikum Bielefeld gemGmbH, Bielefeld, Germany. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Calcitonin, Biomarkers, Tumor, Carcinoembryonic Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medullary thyroid carcinoma is a rare neuroendocrine tumor of parafollicular C-cells. Calcitonin is the primary tumor marker but presents several limitations, including assay variability and false positives in renal dysfunction, proton pump inhibitor use and smoking. Procalcitonin may offer advantages in stability and specificity. To evaluate the diagnostic performance of procalcitonin compared to calcitonin and carcinoembryonic antigen in patients with medullary thyroid carcinoma, we conducted a retrospective study of 60 patients with histologically confirmed medullary thyroid carcinoma at a single endocrine center. Calcitonin, procalcitonin, and carcinoembryonic antigen levels were analyzed pre- and postoperatively over a 4-year period (2015–2019). Statistical analyses included Spearman’s correlation and receiver operating characteristic curve analysis. Subgroup analyses examined the effects of renal dysfunction, proton pump inhibitors, and smoking. Calcitonin and procalcitonin showed a strong correlation (r=0.874 and p0.95 across all years) and remained unaffected by the proton pump inhibitor use or renal impairment. Carcinoembryonic antigen correlated with tumor progression but lacked sufficient specificity alone. The combined use of calcitonin and procalcitonin improved diagnostic accuracy. In all patients with detectable tumor burden, procalcitonin was positive. False-positive calcitonin results were observed in patients without evidence of active diseases but with renal dysfunction or proton pump inhibitor use; procalcitonin remained negative in these cases. Procalcitonin is a reliable tumor marker for medullary thyroid carcinoma, especially in postoperative surveillance. Its stability and independence from common confounders make it a valuable complement to calcitonin. The combined assessment of calcitonin and procalcitonin enhances diagnostic performance and should be considered in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsCalcitoninBiomarkers, TumorCarcinoembryonic AntigenCarcinoma, NeuroendocrineProcalcitoninHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAged

Substanzen

CalcitoninBiomarkers, TumorCarcinoembryonic AntigenProcalcitonin

Autor:innen und Institutionen

  • Academic Department of Endocrinology, Diabetes and Infectiology, Klinikum Bielefeld, Klinikum Bielefeld gemGmbH, Bielefeld, Germany.
  • Internal Medicine & Gastroenterology, Independent Consultant, Marl, Germany.
  • Academic Department of Endocrinology, Diabetes and Infectiology, Klinikum Bielefeld, Medical School and University Medical Centre East Westphalia-Lippe Bielefeld University, Germany, Klinikum Bielefeld gemGmbH, Bielefel…
  • Institute of Medical Laboratory Diagnostics, Microbiology and Transfusion Medicine, University Medical Center OWL, Bielefeld, Germany, Klinikum Bielefeld Mitte, Bielefeld, Germany.
  • Academic Department of Endocrinology, Diabetes and Infectiology, Klinikum Bielefeld, Klinikum Bielefeld, Bielefeld, Germany.

Zitieren

APA

Kopanos, S., Khalil, A. H., Scheel, S. N., Wehmeier, M., & Feldkamp, J. (2026). Procalcitonin as a Tumour Marker in Medullary Thyroid Carcinoma: A Comparative Study with Calcitonin and Carcinoembryonic Antigen. Hormone and Metabolic Research, 58(02), 63-69. https://doi.org/10.1055/a-2794-3447

Vancouver

Kopanos S, Khalil AH, Scheel SN, Wehmeier M, Feldkamp J. Procalcitonin as a Tumour Marker in Medullary Thyroid Carcinoma: A Comparative Study with Calcitonin and Carcinoembryonic Antigen. Hormone and Metabolic Research. 2026;58(02):63-69. doi:10.1055/a-2794-3447

BibTeX
@article{Kopanos2026,
  author = {Kopanos, Stylianos and Khalil, Ahmed Hossam and Scheel, Sandra Nicole and Wehmeier, Michael and Feldkamp, Joachim},
  title = {Procalcitonin as a Tumour Marker in Medullary Thyroid Carcinoma: A Comparative Study with Calcitonin and Carcinoembryonic Antigen},
  journal = {Hormone and Metabolic Research},
  year = {2026},
  volume = {58},
  number = {02},
  pages = {63--69},
  doi = {10.1055/a-2794-3447}
}
Kostenlos starten →